Donhauser Peter D.O.'s Form 4 filing
Anavex Life Sciences Corp. (AVXL) · filed Jun 17, 2024
- Accession no.
- 0001731122-24-000957
- Filed
- Jun 17, 2024
- Trade date
- Jun 14, 2024
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $10.3K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Donhauser Peter D.O.CIK 0001698234 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 14, 2024 | Common Stock | PPurchaseAcquired | +2,835 | $3.64F1 | +$10,319.4 | 5,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Purchase price denominated in Euros has been translated to US dollars using an exchange rate of 0.936
Referenced by the price of 1 transaction in Table I.